Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of engasertib versus placebo in moderate to severe hereditary hemorrhagic telangiectasia
2025-524490-17-00Phase 3Authorised
- Sponsor
- Vaderis Therapeutics AG
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) comparing Engasertib with Engasertib placebo (2 arms). Primary endpoint: Total number of epistaxis events through Week 28. Planned start Sep 2026; status: authorised.
02
Drugs
engasertib
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2025-524490-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524490-17-00.